Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Artec, yeah, I saw that, plus.......
It seems that Rupert has locked himself into another Las Vegas deal.
He doesn't care because he's being paid for them to use his name.
Also, they held a shareholders meeting and announced it a day after the fact.
So far, this has all the "hints" of a scam, but.....
The numbers don't lie and, depending on how it moves, there could be a short play here.(not to mean "shorting")
Puting out a PR to explain a filing indicates that they are into PR pumps................we'll see.
Currant PVCT OS is 10,187,689..eom
PVCT news............
KNOXVILLE, Tenn., Nov 18, 2003 /PRNewswire-FirstCall via Comtex/ --
Provectus Pharmaceuticals (OTC Bulletin Board: PVCT) announced today that the Company is aggressively working to correct erroneous reporting, by individuals, of the increase in the number of free-trading common shares. Reports have been circulated that as many as 1,593,752 more shares have been converted from restricted to free trading shares since September 24, 2003. This number is not correct. Examination of correct SEC filings currently available to the company (Form 144) indicate that between September 24, 2003 and November 17, 2003, only 283,752 shares have been converted from restricted to free trading shares by shareholders.
'It appears that mistakes may have been made by brokers or shareholders as private stockholder's shares were moved to new brokerage accounts, with the holdings being listed as free trading when, in fact, they were not,'said Provectus CEO Dr. Craig Dees. 'We are working directly with the brokers and shareholders to correct any mistakes.'
Provectus Pharmaceuticals, Inc. develops pharmaceutical products in three sectors of the health-care industry: 1) prescription medications, 2) medical devices, and 3) OTC pharmaceuticals and cosmetics. Prescription drug products and devices treat diseases of the skin and many types of cancer. OTC products address complementary markets, primarily those involving skin care and comfort.
The company's corporate offices and laboratory are located at 7327 Oak Ridge Highway, Suite A, Knoxville, Tenn. 37931; 865/769-4012. For more information, contact the company at info@pvct.com or visit the corporate Web site: www.pvct.com
HMDR news.....(surprise..:)
November 17, 2003
LIVERMORE, Calif., Nov 17, 2003 (BUSINESS WIRE) --
Home Director, Inc. (OTCBB: HMDR), reported results today for its third quarter ended September 30, 2003, reflecting a significant reduction in loss as compared to the comparable quarter of 2002. The Company reported a net loss for the quarter of $438,000, as compared to $2,894,000 in the prior year, a decrease of approximately 85%. The net loss for the third quarter of 2002 included other expense, net of $2,120,000 consisting primarily of costs and expenses associated with the convertible notes that were retired on conversion in December 2002. The Company said its continuing cost-reduction programs contributed to the decline.
Total costs and expenses (before other expense, net) of $2,743,000 were down 20% from $3,423,000 in the third quarter of 2002.
Revenues for the quarter were $2,348,000, compared to $2,656,000 in the third quarter of 2002. For the nine months, revenues were $7,309,000 compared to $8,004,000 in the prior year. The Company attributed the revenue decline primarily to reduced hardware sales which were offset in part by increased integration revenues. The decline in hardware sales reflects the effects of several factors, including the Company's strategic decisions to concentrate on cost reduction measures while re-focusing its marketing efforts on the integration sector and the sale of hardware primarily through the still-developing Sears Connected Home program, as well as increasing price competition.
Don Witmer, Home Director's Chairman and Chief Executive Officer, commented: 'This quarter we entered what we hope will be the final stages of our turnaround by continuing to cut expenses while gearing up for expected revenue growth next year as we begin to feel the impact of the Sears Connected Home program and the additional builder contracts we have added in the past several months. Thus far this year we have signed new contracts to provide networking solutions to Shea Homes, Bright Development, SummerHill Homes, Richmond American Homes-Los Angeles Division, Greystone Homes, Cobblestone Homes and Jonathan Homes. '
Recent accomplishments and highlights included: -- At the Electronic Home Expositions, the Company launched its newest addition to the award winning Network Connection Center product line, the MDU or Multiple Dwelling Unit. -- Three industry veterans joined the sales team to support expanded marketing efforts in North America. They are: Mark Boggs - Director Sales, Michael Zarzeczny - National Sales Manager for Canada, and Steve Smith - Account Manager for Southern California. -- Initial results of the Sears Connected Home program were announced by Sears and reflected strong demand for participation in the program by regional integrators seeking certification to install Home Director systems in the program. About the Sears Connected Home program
As part of the Sears Connected Home program, Home Director is matching approved regional integrators with homebuilders to provide networking solutions in new home developments. Distribution merchandising programs are in place at 12 Sears locations throughout the United States and a national advertising program has resulted in hundreds of integrator applications for the Connected Home program.
About Home Director
Home Director designs, manufactures, sells and installs home networking products that it calls the 'The Power Behind Intelligent Living.'These home networking solutions interconnect security systems, audio systems, video services, utilities, personal computers and the Internet. Its products are primarily for installation as basic infrastructure in new homes. Winner of the 2001 Innovative Technology Award from the National Association of Home Builders and Popular Science Magazine, and the 2001 Mark of Excellence Award from the Home Automation and Networking Association, the Company's home networking solutions have been purchased by more than 60,000 home owners in the United States and Canada. Home Director is located in Livermore, California in California's Silicon Valley. To learn more about Home Director, visit www.homedirector.com or call 1-800-426-7144.
This press release includes statements that are not historical facts and are considered 'forward-looking'within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect Home Director's current views about future events. They are identified by their use of terms and phrases such as 'believe,''expect,''plan,''anticipate', 'possibility'and similar expressions identifying their forward-looking character. Investors should not rely on these forward-looking statements as assurances of future events, because such statements are inherently subject to a variety of risks, uncertainties and other factors that could cause actual results to differ materially from the company's expectations. The factors that may affect the outcome of such expectations include the Company's immediate need for additional working capital and other factors detailed from time to time in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-KSB for its fiscal year ended December 31, 2002.
======================================================================SELECTED FINANCIAL DATA(in thousands,except per share data)---------------------------------------------------------------------- (unaudited) Quarter ended Nine months ended---------------------------------------------------------------------- Statements of Operations 9/30/03 9/30/02 9/30/03 9/30/02----------------------------------------------------------------------Revenue $ 2,348 $ 2,656 $ 7,309 $ 8,004----------------------------------------------------------------------Cost of revenue 1,614 1,596 4,469 5,209----------------------------------------------------------------------General &administrative 454 674 1,817 2,496----------------------------------------------------------------------Sales &marketing 519 689 1,822 1,857----------------------------------------------------------------------Research &development 54 184 209 546----------------------------------------------------------------------Depreciation &amortization 101 143 296 609----------------------------------------------------------------------Provision for abandonment of facility --- --- 590 -------------------------------------------------------------------------(Gain) on extinguishments of certain liabilities --- 137 --- (4,523)---------------------------------------------------------------------- Total costs and expenses 2,743 3,423 9,203 6,193----------------------------------------------------------------------Income (Loss) from operations (395) (766) (1,894) 1,812----------------------------------------------------------------------Other expense, net (44) (2,127) (57) (3,007)----------------------------------------------------------------------Net income (loss) $ (438) $ (2,894) $ (1,951) $ (1,195)----------------------------------------------------------------------Comprehensive income (loss) $ (438) $ (2,894) $ (1,951) $ (1,195)----------------------------------------------------------------------Shares used in computing basic and diluted income (loss) per share 3,751,467 625,745 3,751,467 621,850----------------------------------------------------------------------Basic and diluted net income (loss) per share $ (0.12) $ (4.62) $ (0.52) $ (1.92)-------------------------------------------------------------------------------------------------------------------------------------------- Condensed Balance Sheet Data 9/30/02 12/31/02----------------------------------------------------------------------Cash &cash equivalents $ 306 $ 2,557----------------------------------------------------------------------Total assets 10,568 12,003----------------------------------------------------------------------Total shareholders'equity 7,204 9,087----------------------------------------------------------------------
SOURCE: Home Director, Inc.
Investor Contact: Home Director Daryl Stemm, 925-245-2068 or Investor Relations Contact: Cameron Associates Lester Rosenkrantz, 212-554-5486 lester@cameronassoc.com
HMDR 10Q..more about..........
AT 1.20, this stock has been downtrending from an annual high of 8.00.
Coming down from a 1:50 RS in Dec. 02, the OS is only 3.7M
This makes the PPS very volatile and in the last month or two volume has increased.
The fact that the PPS is getting closer to a bottom/bounce price, the rate of decent may increase.
Look for a bottom around a dime, but it could bounce earlier.
(information required to determine a bounce price is sketchy)
The company appears to be making money, but the revenue seems to be decreasing while overhead in increasing.
XKEM news..............
NEW BRUNSWICK, N.J., Nov 17, 2003 (BUSINESS WIRE) --
Xechem International, Inc. (OTCBB: XKEM) today announced that it has received its first patent, #CA2210972, from the Canadian Patent and Trade Mark Office, on October 21, 2003, for its novel, efficient proprietary technology for Isolation and Purification of paclitaxel from Yew tree (Taxus brevifolia and Taxus species). This will protect Xechem's innovative technology which also leads to nine next generation paclitaxel analogs, till the year 2016. Xechem has several U.S. and international patents on its proprietary technology of this cancer drug. Paclitaxel was first approved by the FDA for ovarian cancer under the name of Taxol(R). Subsequently, Taxol was approved for breast cancer, small-cell lung and stomach cancers and AIDS related Kaposi Sarcoma. After becoming one of the largest selling cancer drugs in the world, it has subsequently become available as a generic. Xechem is pursuing a superior proprietary paclitaxel formulation.
'We are delighted to receive the Canadian patent, which protects our technology and further builds credibility for our proprietary paclitaxel,'said Dr. Ramesh C. Pandey, President and CEO of Xechem. 'We believe our formulation may be superior to the generic version.' Dr. Pandey added, 'As we commit our focus to orphan diseases with the development of drugs like HEMOXIN(TM) for Sickle Cell Disease (SCD), a proprietary paclitaxel for potential use in several cancers is a good strategic fit.'
Xechem International, Inc. is a fully integrated biopharmaceutical company focusing on proprietary products for orphan diseases.
This news release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks, uncertainties, including the ability of the Companies to successfully develop and commercialize their technologies, and other factors that may cause the actual results, performance or achievements of the Companies to be materially different from any future results, performance or achievements of the Companies expressed or implied by such forward-looking statements
FNIX news............
SALT LAKE CITY, Nov 16, 2003 (BUSINESS WIRE) --
Fonix(R) Corporation (OTCBB:FNIX), a global provider of leading speech solutions and easy-to-use voice interfaces for devices and systems, announces the availability of our speech interface solution on an educational electronic dictionary manufactured and sold by TopGrade, a leading Chinese manufacturer of embedded devices. TopGrade's device, Kinbible V2100, features the recently announced Fonix/Epson speech solution and is currently on the market. Fonix receives unit royalties from the sale of each device sold, primarily in the Chinese electronic device market. Educational electronic dictionary devices are growing in popularity in China and are expected to exceed a market volume of over 500,000 units per quarter.
Through our partnership with Epson, Fonix has established a working relationship with TopGrade, located in Shenzhen, China, to implement Fonix speech interface solutions in products they manufacture and sell. As their first product offering in this partnership, TopGrade has implemented the Fonix/Epson speech solution in a palm-sized electronic dictionary for Chinese speakers. This valuable educational tool is based on the Fonix/Epson speech solution, which bundles the premier Fonix DECtalk text-to-speech on Epson's powerful processor chips. The Fonix/Epson solution is specifically designed for limited-memory devices.
'The Fonix/Epson speech solution on TopGrade's electronic dictionary provides a superior speech interface for users,'says Samuel Pang, executive director at TopGrade. 'The Fonix solution offers customers the most understandable, accurate voices and makes the Kinbible V2100 an excellent tool for Chinese speakers to learn English.'
'The power of Epson chips gives manufacturers like TopGrade the opportunity to integrate voice interfaces on limited-memory devices,' says Lynn Shepherd, vice president, Fonix Product Development. 'This relationship between Fonix, Epson and TopGrade will expand market opportunities for other TopGrade products incorporating Fonix/Epson speech solutions.'
Visit www.bible.com.cn for information about the Kinbible V2100 (in Chinese).
About Fonix
Fonix Corporation (OTC BB: FNIX) provides speech interface solutions for mobile / wireless devices, computer telephony systems, the assistive market, automobiles and everyday consumer devices. Manufacturers and developers incorporate Fonix technology to provide their customers with an easy, convenient, reliable user experience. Visit www.fonix.com for an introduction to Fonix's suite of speech solutions, or contact a representative at (801) 553-6600 and say 'Sales.'
Investor contact: ECON Corporate Services www.investorideas.com (866) 894-3913
late CYPT PR..................
ALAMEDA, Calif., Nov 14, 2003 /PRNewswire-FirstCall via Comtex/ --
Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, today announced financial results for the third quarter and nine-months ended September 30, 2003.
Revenues for the quarter totaled $897,000, versus revenues of $493,000 for the comparable period in 2002 and $749,000 for the previous quarter ended June 30, 2003. The net loss attributable to common stockholders for the quarter was $7.3 million, or $0.11 per common share, compared to a net loss of $1.5 million, or $0.51 per common share for the three months ended September 30, 2002. The net loss for the third quarter of 2003 and 2002 included a $4.8 million loss and a $1.3 million gain, respectively, in non-cash items that were primarily related to the grants of common stock, options and warrants as compensation for services and non-cash interest expense related primarily to the accounting for Calypte's convertible debt financing instruments.
For the nine months ended September 30, 2003, revenues totaled $2.4 million, versus revenues of $2.9 million for the same period last year. The net loss attributable to common stockholders was $21.6 million, or $0.75 per common share, compared to a net loss of $7.2 million, or $3.41 per common share for the nine months ended September 30, 2002. The net loss for the nine months ended September 30, 2003 and 2002 included a $12.8 million loss and a $2.1 million loss, respectively, in non-cash items that were primarily related to the grants of common stock, options and warrants as compensation for services and non-cash interest expense related primarily to the accounting for Calypte's convertible debt financing instruments.
'Calypte has met challenges this quarter and is continuing to pursue its international marketing goal for rapid urine testing and this product development cycle,'stated Tony Cataldo, Calypte's Executive Chairman. 'The HIV/AIDS testing market is vast and Calypte is dedicated to achieving a significant penetration into that market in the coming quarters.'
Following are the company's most significant milestones since the last quarterly release together with the progress made in the development of its rapid HIV products and the strengthening of the balance sheet:
* The company submitted an application with the U.S. Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) for its HIV-1/2 lateral flow antibody Rapid Blood Test to be performed on whole blood. This represents the Company's first application in connection with several rapid HIV diagnostic tests the Company has under development. The Company expects to submit a similar application for its urine-based HIV-1/2 Rapid Test sometime next year. * The company believes that there is strong demand for a rapid urine product and is moving forward with international clinical trials and is in the initial planning stages to establish the manufacturing locations necessary to produce product and file for approvals in key African countries as well as China. Further to this end, as part of its association with the Marr Group, it is forming a joint venture in China to manage this important market. * Calypte completed a $10 million equity financing agreement with Marr Technologies, B.V. via the issuance of 20,000,000 restricted shares of common stock at a price of $.50 per share. * Calypte also concluded a $10 million debt facility from Marr Technologies, B.V. this week. The monies can be drawn down during next spring in the form of 12-month notes bearing simple interest at 5%. In order to obtain full access to the line the company has committed to moving to a major stock exchange no later than the end of the first quarter of 2004. This provides an extra $10 million in available working capital in 2004, as necessary, while the company seeks to bring its HIV rapid products to market.
Calypte exited the quarter ended September 30, 2003 with $9.0 million in cash, $6.5 million in working capital, and a 9-month average burn rate for 2003 of $1.1 million.
Commenting on these events, Mr. Oyakawa, Calypte's President and Chief Operating Officer stated, 'We believe we now have sufficient capital to execute most of our business plan. Our focus for the next two quarters will be operations -- en route to rapid urine revenues, which we anticipate no later than the summer of next year. Execution of these goals will be the highest priority.'
Further information is available in the company's SEC Form 10-QSB filed earlier today. As noted therein, Calypte was contacted by the San Francisco District Office of the Securities and Exchange Commission (the 'Commission') on October 28, 2003 and advised of an informal inquiry being conducted by the enforcement staff of the Commission regarding the Company. The staff has requested, among other things, documents and information related to certain press releases issued by the Company. The Commission has advised the Company that the inquiry should not be construed as an indication by the Commission or its staff that any violation of law has occurred. The Company is in the process of voluntarily providing information sought by the Commission and intends to cooperate with the Commission in connection with its informal inquiry. Independently, the Company's Audit Committee is investigating the matter and intends to make recommendations, if applicable, to the board of directors. Calypte's independent auditors, KPMG LLP, have informed the Company that they will not complete their quarterly review until such time as the Company's Audit Committee completes its investigation and the same is reviewed by KPMG LLP.
Calypte management will host a conference call Monday November 17, to discuss the Company's third quarter financial results as well as provide an update on the Company's current activities at 12:00 p.m. Eastern Time.
The call can be accessed in the U.S. by dialing 800-901-5217 and outside of the U.S. by dialing 617-786-2964. The participant passcode is 58765973. The conference call will also be Web cast live at www.calypte.com. An audio replay of the call will be available, beginning approximately 1 hour after the conference call ends, by dialing 888-286-8010 in the US, or 617-801-6888 from outside of the U.S. The account code for the playback is 13337320. The webcast will also be available for replay on the company's website.
About Calypte Biomedical
Calypte Biomedical Corporation, headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approved serum HIV-1 antibody Western Blot test. The Company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ('SEC'), including its annual report on Form 10-K for the year ended December 31, 2002 and its subsequent filings with the SEC.
SHRN filed NT 10Q,..more about.....
Last Aug 21 the company paid a first ever stock dividend of 8%
It normally trades on very light volume, but today it traded an exceptionally heavy volume of 1.4M shares and is up 22% at .005
Now, almost three months after the stock dividend was paid, it's a good bet that investors are jumping onboard in anticipation of another dividend.
Aside from today's uptic, I don't see much on the chart, but Monday's pre-bell activity, if any, will tell a lot....IMO
MSGL filed NT 10Q...more about.........
Currently trading at .13, but downtrending
Last month it bounced from about .035 to .25
Watch for it to drop below .05 before it bounces again.
TALL & MXDY filed NT 10Q..eom
USGA filed 10QSB, up 70%..eom
USXP filed 10Q..more about....
This is an interesting way to show the amount of shares outstanding;
State the aggregate market value of the voting stock held by non-affiliates of
the registrant on September 30, 2003:
--------------------------------------------------------------------------------
$24,159,776
--------------------------------------------------------------------------------
Indicate the number of shares outstanding of each of the issuer's classes of
common stock as of the latest practicable date.
--------------------------------------------------------------------------------
Common Stock Outstanding at September 30, 2003
--------------------------------------------------------------------------------
Class "A" 552,027,232
Class "B" 1,280,000
dubsy, speaking of natural gas, you might find this interesting.
Take a look at the product these guys have..
http://www.hydrogenerate.com
SWEB news............
VANCOUVER, B.C., Nov 14, 2003 (PRIMEZONE via COMTEX) --
Stockgroup Information Systems Inc. (OTCBB:SWEB) (TSX-V:SWB) a financial media and technology company, today announced its third quarter results for the period ending September 30, 2003.
Third Quarter 2003 Operational Highlights
- Revenue increased 32% - Gross profit increased 74% - Gross profit margin increased to 80% compared to 61% in Q3, 2002 - Paid off all outstanding notes to become debt free - Fourth consecutive quarter of increasing revenues and gross profits
Third Quarter 2003 over Third Quarter 2002 (all figures in US dollars)
2003 third quarter revenues were $745,801, up 32% from $563,481 during the same quarter in 2002. Third quarter gross profit is $595,272, up 74% from $341,352 from the same quarter in 2002. Gross profit margin increased to 80% for the third quarter of 2003 compared to 61% for the third quarter of 2002. The net loss for the quarter is ($275,896) ($0.01 per share) compared to ($310,436) ($0.02 per share) in the third quarter of 2002.
As at September 30, 2003 the Company had cash and cash equivalents of $860,064 compared to $553,358 as at June 30, 2003. The Company has no debt except for normal accounts payables having paid off all other debt in September 2003 compared to $1,764,862 of debt at September 30, 2002.
'During Q3 Stockgroup became debt free, institutional investors started buying our shares again, and we began seeing the results of our partnership with Associated Press', said Marcus New, Chairman and CEO of Stockgroup Information Systems Inc. 'The Company's results for Q3 represent a continuing trend for Stockgroup as revenues continue to increase incrementally and profitability remains a core focus.'
Second Quarter 2003 to Third Quarter 2003 (all figures in US dollars)
2003 third quarter revenues were $745,801, an increase of 8% from the second quarter of 2003 revenue of $688,529. Third quarter gross profit is $595,272 up 16% compared to $512,197 for the quarter ended June 30,2003. Gross profit margin increased to 80% in the third quarter of 2003 compared to 74% in the second quarter of 2003. For the previous quarter ended June 30, 2003, net loss improved to ($275,896) ($0.01 per share) from ($893,737) ($0.04 per share) a 69% decrease in net loss.
Nine Month Period 2003 compared to Nine Month Period 2002 (all figures in US dollars)
For the nine months ended Sept 30, 2003 revenues increased 44% to $2,036,042 compared to $1,413,425 at Sept 30, 2002. The nine-month's period gross profit is $1,551,827, up 81% compared to $857,790 for the same period in 2002. Gross profit margin for the nine-month period ended Sept 30, 2003 is 76% compared to 61% for the same period in 2002.
Third Quarter 2003 Highlights - Completely debt free - Stockgroup announced the early repayment of all outstanding notes. - Revenues continue to increase quarter over quarter - This marks the fourth consecutive quarter of increasing revenues. - Associated Press signs four clients to license Stockgroup Solution - St. Petersburg Times, Orange County Register, Sphere Analytics and DataCall. - Canadian Press licenses CP/Stockgroup Solution to five new customers - Mackenzie Financial, Altamira, Research Capital, Quebec City's Le Soleil, and Sun Media Group.
A summary of the financials is attached. A conference call to discuss these results will be held today, Friday November 14, 2003 at 10:00 a.m. PST. Analysts, investment professionals, shareholders, members of the media and other interested parties wishing to participate may call 1.866.207.8482 (toll free) five minutes prior to the scheduled time. Alternatively, you may listen to a live audio Webcast of the conference call at http://www.stockgroup.com.
The call will be archived at http://www.stockgroup.com. Select 'Investors'at the top of the page, and then select 'Conference Call'in the navigation bar. This earnings call will be accessible using Windows Media Player for a period of one year.
For full details please view our 10QSB filed today on EDGAR.
QTFV news................
November 14, 2003
WESTLAKE VILLAGE, Calif., Nov 14, 2003 /PRNewswire-FirstCall via Comtex/ --
QT 5, Inc. (OTC Bulletin Board: QTFV), manufacturer, distributor and marketers of biomedical diagnostics and NICOWater(TM), a Homeopathic Nicotinum Formula, today announced it has submitted their recently acquired ten-minute HIV1 and HIV2 qualitative diagnostic kit to the office of the Army's Surgeon General.
'Although our HIV test is still in Phase 3 of the FDA approval process; the word is out about the exciting potential of our entire patented diagnostic platform,'said QT 5, Inc. CEO Timothy Owens. 'In addition to impressive private, institutional and local government markets, the United States Federal Government represents the single largest user base for QT 5 diagnostics. It is no mistake that all of our medical, scientific and regulatory advisors are widely recognized and well respected for their influence in the advancement of the biomedical sciences. As a result of our preliminary market research, QT 5 leadership has been actively presenting our products to many high level decision makers within the Federal Government. This most recent opportunity was in response to a written request from U.S. Army's Purchasing Review Dept.'
About QT 5, Inc.
QT 5, Inc. is a Delaware corporation formed in April 1999 as a manufacturer, distributor and marketer of biomedical testing and Homeopathic products. QT 5, Inc. currently manufactures and markets NICOWater, its breakthrough Homeopathic Nicotinum (nicotine) product designed to relieve the symptoms of tobacco cravings. QT 5, Inc. continues to do research and development regarding future products for lifestyle enhancements. QT 5, Inc. is headquartered in Westlake Village, California. For more information on the Company please visit: www.qt5inc.com. NICOWater(TM) is a Homeopathic Drug product that is sold under the FDA's Compliance Policy Guide Conditions Under Which Homeopathic Drugs May Be Marketed.
secure, PFCE looks like it's on its way back up(.38)
I think that was just healthy profit taking, but I had hoped it would dip lower........oh well....:)
secure, PFCE looks like it's on its way back up(.38)
I think that was just healthy profit taking, but I had hoped it would dip lower........oh well....:)
QTFV news.....................
WESTLAKE VILLAGE, Calif., Nov 13, 2003 /PRNewswire-FirstCall via Comtex/ --
QT 5, Inc. (OTC Bulletin Board: QTFV), manufacturer and marketers of NICOWater(TM), the breakthrough Homeopathic Nicotinum (nicotine) product designed to relieve the symptoms of tobacco cravings, today announced the addition of four new distribution partners in the Northeastern U.S. The group includes; Bull Dog Beverage serving Northern New Jersey and all five boroughs of New York City, Native Wholesale Company serving Central New York, Northern Pennsylvania and all of West Virginia, Amoskeag Beverages, Inc. serving all of New Hampshire, and Bev Net who will be taking over the Connecticut markets.
'We continue to recruit and secure new distributors at an aggressive pace,'said Steven H. Reder, QT 5, Inc. President. 'Since we first announced the availability of NICOWater(TM), we have been flooded with interest from distributors, dealers and consumers. In strict adherence to our rollout strategies, we have been very careful to assure the capability, credibility and potential of each new partner. I am proud to say that each of these new NICOWater(TM) distributors are recognized leaders in their channels.'
About QT 5, Inc.
QT 5, Inc. is a Delaware corporation formed in April 1999 as a manufacturer, distributor and marketer of Bio-Med testing and Homeopathic products. QT 5, Inc. currently manufactures and markets NICOWater, its breakthrough Homeopathic Nicotinum (nicotine) product designed to relieve the symptoms of tobacco cravings. QT 5 continues to do research and development regarding future products for lifestyle enhancements. QT 5, Inc. is headquartered in Westlake Village, California. For more information on the Company please visit: www.qt5inc.com. NICOWater(TM) is a Homeopathic Drug product that is sold under the FDA's Compliance Policy Guide Conditions Under Which Homeopathic Drugs May Be Marketed.
secure, nah, that's just when they run. I slept in day before yesterday and missed that 900% run on ENCU.
There are a lot of interesting stocks coming into play and the market, after about two years, is starting to look healthy.
dsertrat, while waiting for the news EXTI could be a good short play.
I put it on my radar and at .46 it's taking a hit today.
From the charts, this could drop all the way down to the 20s, maybe lower.
If it does, it could be in for a nice bounce....
I also put ADVC on my radar.
There, I'm looking for a bottom back down around .002
I'll have a better feel for it after today.
good picks guy......thanks.
dsertrat, Boy! What a ride EXTI is...
My chart show a support level right about where it is now, (.50), but if it breaks through that, look out below!
Do you know anything about the company?
I didn't see any specific PRs that would have made it run as it did.
What prompted this run?
secure, it looks like profit taking may be pushing PFCE down.
This could turn into a good play.
QTFV filed a 10Q after the bell......
As of yesterday, the OS is 46,614,457 shares.
Here's a statement from the filing;
Transition To Operating Company
We have transitioned from a development stage enterprise to an operating company and have only recently begun to generate revenues from sales of our initial product NICOWater(TM). All losses accumulated from inception through our last fiscal year ended June 30, 2003 have been considered as part of our development stage activities. Although we anticipate increased revenue, we will require substantial additional financing for sales and marketing, general business
overhead, continuing research and development and obtaining regulatory approval for and the commercialization of products. There can be no assurances that our operations will be profitable or that we will be able to obtain sufficient
additional financings when they are needed, or that such financings will be obtainable on terms satisfactory to us. Our products, to the extent they may be deemed medical devices or biologics, are governed by the Federal Food, Drug and
Cosmetics Act and by the regulations of various state and foreign governmental agencies. There can be no assurance that we will maintain or obtain the appropriate regulatory approvals required to market our products.
INCREASE IN AUTHORIZED COMMON SHARES
On October 8, 2003, we filed a Definitive Form 14C with the Securities and Exchange Commission stating that our Board of Directors and shareholders of record as of the close of business on September 22, 2003 holding a majority of
the total number of outstanding shares consented to increase the number of shares of authorized common stock from 100,000,000 to 300,000,000. The par value of each such share of common stock was changed to $0.001 per share. The
Certificate of Amendment of Certificate of Incorporation has been filed with the Secretary of the State of Delaware.
Wadda day!...I should change the background on my streamer to green.
Then it would look like Christmas.....all red and green!
hey yo, What's going on with PACC?..
Is it just a hunch or do you have some details?
I have to admit, I'm pretty skeptical about this company.
They got me good a few months ago with their now-you-have-it now-you-don't spinoff stock dividend.
So, wazzup?
QTFV news..............
November 12, 2003
WESTLAKE VILLAGE, Calif., Nov 12, 2003 /PRNewswire-FirstCall via Comtex/ --
QT 5, Inc. (OTC Bulletin Board: QTFV), manufacturer, distributor and marketers of biomedical diagnostics and NICOWater(TM), a Homeopathic Nicotinum Formula, today announced it is a key participant in a recent Homeland Defense Dept. proposal to develop a robust compact system capable of autonomously monitoring outdoor urban areas for a broad range of biological agents. The proposal was submitted by MATECH Advanced Materials, a recognized global leader in the areas of optical and electronic sciences, bio-materials and high temperature ceramics. QT 5, Inc. will be providing the cassettes and membranes employed by the system.
This opportunity is a direct result of QT 5, Inc.'s recently announced acquisition of an extensive line of patented biological diagnostic devices and platforms. Company Medical Advisor Howard J. Wilner, M.D. states, 'The QT 5, Inc. diagnostic platform is a cost effective solution for the rapid qualitative and quantitative analysis of a wide variety of infectious agents, including those biological threats which are of greatest concern to our Homeland Defense Dept.'Dr. Wilner has served as the Clinical Chief of Medicine at Cedars-Sinai Medical Center as well as the Executive Director of the Cedars-Sinai Comprehensive Cancer Center from 1988 through 1997.
According to QT 5, Inc. CEO Timothy J. Owens, 'We are quickly learning that the opportunities and applications of our diagnostic products are even more far-reaching than we anticipated. By securing the right to market these products under the manufacturer's existing US Dept. of Defense and US Dept. of Justice numbers, we have been propelled into one of the largest potential current and future user bases for these products.'
About QT 5, Inc.
QT 5, Inc. is a Delaware corporation formed in April 1999 as a manufacturer, distributor and marketer of biomedical testing and Homeopathic products. QT 5, Inc. currently manufactures and markets NICOWater, its breakthrough Homeopathic Nicotinum (nicotine) product designed to relieve the symptoms of tobacco cravings. QT 5, Inc. continues to do research and development regarding future products for lifestyle enhancements. QT 5, Inc. is headquartered in Westlake Village, California. For more information on the Company please visit: www.qt5inc.com. NICOWater(TM) is a Homeopathic Drug product that is sold under the FDA's Compliance Policy Guide Conditions Under Which Homeopathic Drugs May Be Marketed
Linchuck, Aye, tis time to be alert..eom
dubsy, glad you could make it,(and improve your education at the same time...:)
You will find zero bashing, pumping, spamming or BS here.
We share info, hopes, predictions, and expectations about stocks......
Too bad you missed dsertrat's info about ENCU yesterday.
It ran for about 900-1000% today, starting at just over a penny or two.
Man!......I wish we could see those every day....(once a week would be nice too...:)
Don't be a stranger.......and if you have a pick, DD or whatever, please share it.
TIA
QTFV, to get an idea of the potential of this company read the last few PRs.
The OS is about 38.3M and trading volume for the last couple of day is flying.
It closed today at .135, up from .105
dsertrat, yeah, I really was planning to....
didn't get up until 9AM......
Serves me right for not going to bed until 4AM....:)
But, QTFV might make up for it......(well, kinda)
I'm in at .105 and it made some nice moves in the last couple of hours......
I really like what they are doing and they have one hell of a market to sell into..
I saw 193K sold AH at .128, so there may be a dip at the opening, but I'll be surprised if it's through.
QTFV closed at .135, up from .105.eom
Thanks slow, there was only one S-8 filed for QTFV after the 10Q in May.
That one was for 5M shares, which brings the OS up to about 38-9 M.......still not too shabby.
The SB-2A shares,(about 53M), shouldn't be part of the OS yet.
Oops, Hey,,,I just noticed!!!
That 10Q for QTFV shows as of 1996!.......ARRRRGGGGGHHHH!
This, from the May 03 10Q
As of May 9, 2003 the Company had 33,237,428 shares of its $.001 par
value common stock issued and outstanding.
Sorry......:).........damn!.......I'm not supposed to be less than perfect on Tuesdays......:)
From QTFV 10Q..........
FORM 10-QSB
Quarterly Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
For Quarter Ended June 30, 1996 Commission File No. 0-25022
CHELSEA ATWATER, INC.
(Exact name of Registrant as specified in its charter)
NEVADA 72-1148906
(State or other jurisdiction of (I.R.S. Empl. Ident. No.)
incorporation or organization)
90 Madison Street, Suite 707
Denver, Colorado 80206
(Address of Principal Executive Offices) (Zip Code)
(303) 355-3000
(Registrant's Telephone Number, including Area Code)
Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or such shorter period that the Registrant was required
to file such reports), and (2) has been subject to such filing to such filing
requirements for at least the past 90 days.
Yes X No
The number of shares outstanding of each of the Registrant's classes of common
equity, as of June 30, 1996 are as follows:
Class of Securities Shares Outstanding
Common Stock, $.001 par value 622,649
hey yo, I've seen stocks trade more than they have OS, haven't you?
But, FWIW, those numbers came from the 10Q filed last August and, besides the SB-2A they haven't filed anything showing the regiatration of more shares.....
I'll recheck the 10Q
QTFV, news.....and about......
Several months ago, when I first heard of Nicotine-drinking water, I was skeptical.
I thought the FDA would step in and put all kinds of restrictions on it.............but that never happened.
Now, they are not only marketing this stuff, but they have signed up several major drug chains to carry it.
For those who aren't familiar with the drug Nicotine, it's a good drug that has received very bad PR.(thanks to the anti-smoking movement)
the OS on QTFV is only 622,649K shares.
On 10/1 they filed a SB-2 to register about 60M shares.
Today, they filed a SB-2A for the same thing, but with a slight amendment.
This filing is NOT for the immediate release and sale of all those shares.
For the most part, they were registered to cover warrants that have a long way to go before they can have value and some CD conversions.
Since there have been no filings related to CD conversions, the OS should still be around 622K.
That should make the PPS VERY volatile,.......but.....
It appears that investor reactions to these SB-2 filings may be holding the PPS down and even making it look weak.....
This could be a sleeper........IMO
Here's today PR........
TUESDAY, NOVEMBER 11, 2003 1:27 PM
QTFV
0.104 -0.006
WESTLAKE VILLAGE, Calif., Nov 11, 2003 /PRNewswire-FirstCall via COMTEX/ -- QT 5, Inc. (QTFV) , manufacturer and marketers of NICOWater(TM), the breakthrough Homeopathic Nicotinum (nicotine) product designed to relieve the symptoms of tobacco cravings, today announced it has finalized the exclusive worldwide rights to market an innovative line of rapid-result blood and urine test products. The diagnostic platform has been specifically designed for point-of-care and ambulatory use, as well as providing an ideal development platform for the emerging Homeland Defense market.
The patented test platform incorporates a unique combination of a solid phase membrane and combinations of immunologically based reagents in a single-use disposable test device. The platform has the capacity for providing rapid, point-of-care testing for a wide variety of medical conditions. This diagnostic platform is highly flexible, being capable of testing for a wide variety of important infectious diseases, drugs and their metabolites. Depending upon the application, this platform technology may provide either quantitative or qualitative test results in minutes with a high degree of accuracy.
Diagnostic Products
The current product line includes a number of qualitative and quantitative blood tests that have already received FDA approval. These include qualitative tests that detect within minutes the presence of rubella, herpes virus, rotavirus, strep group A, infectious mononucleosis and early pregnancy.
HIV1 & HIV2 Tests
QT 5, Inc. also announced that it has acquired a 10-minute HIV1 and HIV2 test that is currently in the final stages of FDA Phase 3 testing for ease-of- use. This test procedure represents a significant improvement over currently available diagnostic products that can only detect HIV 1 and take a full 20-minutes before the results are available.
Quantitative Assay Analyzer
QT 5, Inc. will include in its initial product offering, a low-cost small footprint, desktop analyzer designed for use with the rapid test cartridges. The FDA approved analyzer is currently capable of rapidly detecting quantitative data for myoglobin, CK-MB, cardiac troponin-1, as well as the presence and volume of cocaine. A hand held mobile version of the multiple assay analyzer that will be compatible with a wide variety of new tests is also being developed for use by paramedics, assisted living facilities and the military. The mobile assay analyzer will provide a low cost field upgradeable system available for use at point of suspected infection anywhere in the world.
Drug Tests
The Company will also include a low-cost rapid result drug test in the initial product line introduction. The test utilizes a rapid immunochromatography assay to detect the presence of drug metabolites in urine. The test is completely self-contained and the results are visibly displayed on the test cup.
According to QT 5, Inc. CEO Timothy Owens, "This is a very exciting new product line that will allow us to continue to grow our business in many of the markets we have been targeting since our very founding. In addition to the exclusive rights for these patented products, we have also secured the right to market these products under the manufacturer's existing US Dept. of Defense and US Dept. of Justice numbers. This will allow us to immediately pursue Federal contracts representing one of the largest potential current and future user bases for these products."
About QT 5, Inc.
QT 5, Inc. is a Delaware corporation formed in April 1999 as a manufacturer, distributor and marketer of biomedical testing and Homeopathic products. QT 5, Inc. currently manufactures and markets NICOWater, its breakthrough Homeopathic Nicotinum (nicotine) product designed to relieve the symptoms of tobacco cravings. QT 5, Inc. continues to do research and development regarding future products for lifestyle enhancements. QT 5, Inc. is headquartered in Westlake Village, California. For more information on the Company please visit: www.qt5inc.com. NICOWater(TM) is a Homeopathic Drug product that is sold under the FDA's Compliance Policy Guide Conditions Under Which Homeopathic Drugs May Be Marketed.
WAVX news...................
LEE, Mass. &NEW YORK, Nov 11, 2003 (BUSINESS WIRE) --
Wave Systems Corp. (Nasdaq: WAVX - www.wave.com), a leader in delivering trusted computing web-based applications and services with advanced products, infrastructure and solutions across multiple trusted platforms, today announced it has been invited to participate in seminars in the United States this week to promote FINREAD specifications.
Wave offers for license a hardware platform architecture that runs software based on FINREAD specifications made available by the European Commission Information Society Program. This software can deliver secure consumer applications for trusted input devices, such as next-generation secure smart card readers and trusted personal computers.
FINREAD, led by Groupement des Cartes Bancaires, along with SIZ, Banksys, Interpay, Europay, VISA and others, establishes standards and specifications for smart card readers and advanced e-commerce terminals used in home banking, shopping and other services for the deployment of interoperable, secure smart card terminals.
The FINREAD Consortium has held Information Days in Asia, Europe and the U.S. Wave participated in the most recent session held in San Francisco on November 10 and has also been invited to offer FINREAD demonstrations in New York City, on November 14, at Le Parker Meridien Hotel, 118 West 57th Street. The FINREAD Information Day lasts from 8:30 a.m. through 5:00 p.m. For more information, please visit http://www.finread.com/registration or contact Bruno Leconte, Wave vice president, European Operations, at bleconte@wavesys-emea.com.
Each seminar gives a general overview of the business requirements, functions, security features and architecture of FINREAD. In-depth technical information is also detailed, providing a solid base for potential hardware and software developers of FINREAD e-commerce solutions.
Wave's hardware-based, open, programmable EMBASSY(R) technology embeds trust and security in user devices, enabling strong authentication, and reliable, secure digital exchange and commerce. Licensed EMBASSY technology is ideally suited to applications such as FINREAD where secure tamper resistant execution, tight integration with smart cards, and secure input and output services are required.
FNIX news..............
SALT LAKE CITY, Nov 11, 2003 (BUSINESS WIRE) --
Fonix(R) Corp. (OTC BB: FNIX), an international provider of leading speech interface solutions, announces a cooperative technology partnership with a-technic, a nonprofit research and development charity, to promote Fonix DECtalk(TM) text-to-speech (TTS) as a speech technology solution to clients and partners.
a-technic researches and develops products for blind, low-vision and disabled technology users, then makes that technology available to other organizations to market and sell end-user products. By incorporating DECtalk into their easy-to-use computer platform, a-technic offers their manufacturing partners the most intelligible TTS voices available.
Fonix DECtalk is the premier TTS solution in today's speech industry due to its high intelligibility, low memory footprint, nine voices (four male, four female, one child) and multiple languages (U.S. and U.K. English, European French, German, Castilian and Latin American Spanish).
'a-technic needs a compact, intelligible, flexible and stable TTS solution for development of our low-cost, easy-to-use talking computer appliances for blind users,'said John Batty, a-technic CTO. 'Fonix DECtalk is clearly the best product on the market for meeting these requirements.'
'This partnership is a great opportunity for both Fonix and a-technic,'said John Oelfke, vice president of Fonix Embedded Speech Solutions. 'Working together, we can offer the best speech-based interface technology currently available to the assistive market. Our mutual goal is to make it easier and more convenient for visually impaired, blind or disabled people to access computers and devices.' As a-technic's products are made available to their manufacturing partners for deployment to the user community, Fonix will receive royalty revenue from these sales.
About a-technic
a-technic is a U.K.-registered charity specializing in technology to help people with disabilities.
Their mission is to research, develop and promote adaptive and assistive technologies that help people with physical disabilities cope with day-to-day living. Visit www.a-technic.net for more information.
dsertrat, HOW FRUSTRATING!......
Last night I spent a bit of time reading the 10Q for ENCU, the PRs, etc and planned to watch it before the opening bell.....and jump on if it looked like it would move.
I OVERSLEPT!.........and only got up about 15 minutes ago!
OH, no big deal.......it's only up about 900%!!!
It's a good thing I have a short memory span.....the pain won't last too long....:)